Citations available for content in Chicago, APA and MLA format.
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Notice. "Determination of Regulatory Review Period for Purposes of Patent Extension; Vyndamax" Federal Register 89, no. 203 (October 21, 2024): 84161-84163. https://www.govinfo.gov/app/details/FR-2024-10-21/2024-24187.
Office of the Federal Register, National Archives and Records Administration. (). 89 FR 84161 - Determination of Regulatory Review Period for Purposes of Patent Extension; Vyndamax. [Government]. Office of the Federal Register, National Archives and Records Administration. https://www.govinfo.gov/app/details/FR-2024-10-21/2024-24187
Office of the Federal Register, National Archives and Records Administration. 89 FR 84161 - Determination of Regulatory Review Period for Purposes of Patent Extension; Vyndamax. Office of the Federal Register, National Archives and Records Administration, , https://www.govinfo.gov/app/details/FR-2024-10-21/2024-24187
Office of the Federal Register, National Archives and Records Administration, Determination of Regulatory Review Period for Purposes of Patent Extension; Vyndamax, govinfo, (October 21, 2024), https://www.govinfo.gov/app/details/FR-2024-10-21/2024-24187.
Close xFederal Register Volume 89, Issue 203 (October 21, 2024)
Regulatory Information
Federal Register
AE 2.7:
GS 4.107:
AE 2.106:
Office of the Federal Register, National Archives and Records Administration
Notices
Notice.
Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by December 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 21, 2025. See "Petitions" in the SUPPLEMENTARY INFORMATION section for more information.
Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6200, Silver Spring, MD 20993, 301-796-3600.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYNDAMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
84161-84163
89 FR 84161
Docket No. FDA-2022-E-3123
2024-24187